Skip to main content
Sign In

Bryan Haugen, M.D.

Professor of Medicine & Pathology Head, Division of Endocrinology, Metabolism & Diabetes
Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research

Since finishing training at the University of Colorado Health Sciences Center in 1993, Dr. Haugen has been interested in the molecular mechanisms governing thyrotrope function and thyroid neoplasms. His current clinical interests include thyroid neoplasms, advanced thyroid cancer, thyroid dysfunction and other endocrine tumors (parathyroid, adrenal, carcinoid).  Dr Haugen’s research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets.  Specific areas of research include nuclear hormone receptors (RXR, TR, PPAR) and kinase signaling pathways as therapeutic targets in thyroid cancer, as well as proteomic approaches to molecular markers in thyroid neoplasms.  His research group is also actively studying novel regulation of the hypothalamic-pituitary-thyroid axis.

Selected Publications​

  • French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP and Haugen BR. Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer. J Clin Endo Metab 95:2325-33, 2010. PUBMED
  • Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL and Tuttle RM. Revised American Thyroid Association Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:1167-1214, 2009. PUBMED
  • Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL and Haugen BR. Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer. J Clin Endo Metab 94:2199-2203, 2009. PUBMED
  • Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC and Haugen BR. DNA Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. J Clin Endo Metab, 93:4331-41, 2008. PUBMED
  • Netea-Maier RT, Hunsucker SW, Hoevenaars B, Helmke SM, Slootweg P, Hermus A, Duncan MW, and Haugen BR. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Research 68:1572-80, 2008. PUBMED
  • Golden W, Weber KB, Hernandez TL, Woodmansee WW, Sherman SI, and Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endo Metab, 92:124-30, 2007. PUBMED
  • Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, and Haugen BR. RXRg and PPARg expression predicts< thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 3:1011-1020, 2004. PUBMED
  • Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, and Sharma V. Retinoic acid and retinoid X receptors are differentially expressed expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endo Metab 89:272-280, 2004. PUBMED
  • Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, and Haugen BR.  Thyroid hormone resistance and increased metabolic rate in the RXRg deficient mouse. J Clin Invest 106:73-79, 2000. PUBMED


M.D., Mayo Medical School, Rochester, MN (1987)

Research Interests

  • Thyroid Diseases
  • Endocrine Neoplasms​​​